| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Reactive oxygen species (ROS) / free radicals. Antioxidant agent-7 acts as a direct free radical scavenger, particularly targeting DPPH radicals, and likely reduces lipid peroxyl radicals, thereby preventing oxidative damage to cellular membranes.
|
|---|---|
| ln Vitro |
Antioxidant agent-7 scavenges DPPH free radicals with an IC50 of 470 nM, indicating potent antioxidant activity in cell-free systems. It protects cell membrane integrity by scavenging free radicals and mitigating lipid peroxidation in oxidative stress models.
|
| ln Vivo |
No specific in vivo data reported. However, based on its antioxidant properties, it may reduce oxidative damage in animal models of inflammation or ischemia-reperfusion injury. Further in vivo studies are needed to confirm its efficacy and safety.
|
| Enzyme Assay |
Antioxidant agent-7 is dissolved in DMSO or methanol at concentrations ranging from 0.1-100 uM. The DPPH radical scavenging assay is performed by mixing 100 uL of compound solution with 100 uL of 0.1 mM DPPH in methanol. After 30 minutes incubation at room temperature in the dark, the absorbance is measured at 517 nm. The percentage of scavenging activity is calculated as [(Acontrol - Asample)/Acontrol] × 100%. IC50 is determined by nonlinear regression.
|
| Cell Assay |
Cell culture models of oxidative stress (e.g., neuronal SH-SY5Y cells or hepatocytes) are seeded in 96-well plates at 1×10⁴ cells/well and treated with Antioxidant agent-7 (1-100 uM) for 24 hours. Oxidative stress is induced by adding H2O2 (100-500 uM) or tert-butyl hydroperoxide. Cell viability is assessed by MTT assay. Intracellular ROS levels are measured using DCFH-DA fluorescent probe. Lipid peroxidation is evaluated by malondialdehyde (MDA) assay.
|
| Animal Protocol |
No in vivo animal study protocols are specifically documented. For potential in vivo evaluation, a typical protocol might involve oral or intraperitoneal administration of Antioxidant agent-7 (5-50 mg/kg) once daily for 7-14 days in rodent models of oxidative stress (e.g., CCl4-induced hepatotoxicity or ischemia-reperfusion injury). Endpoints include serum biomarkers of oxidative damage, tissue histopathology, and measurement of antioxidant enzyme activities (SOD, CAT, GPx).
|
| ADME/Pharmacokinetics |
Cannot be extracted; information not available. Antioxidant agent-7 is a small molecule suitable for oral administration due to its moderate molecular weight (363.41) and predicted moderate lipophilicity (LogP ~3-4). However, no ADME data has been published. Investigators are encouraged to conduct preliminary PK studies: typical parameters include oral bioavailability, half-life, and clearance using LC-MS/MS analysis of plasma.
|
| Toxicity/Toxicokinetics |
No dedicated toxicity studies are available. Antioxidant agent-7 at concentrations up to 100 uM in cell culture does not induce cytotoxicity; however, formal toxicological assessment has not been conducted. As a benzodiazepine derivative, off‑target CNS effects cannot be ruled out without additional profiling. It is intended for research use only.
|
| References |
[1]. Bhagat K, et al. Microwave-assisted synthesis of 11-substituted-3,3-dimethyl-2,3,4,5,10,11-hexahydrodibenzo[b,e][1,4]diazepin-1-one derivatives catalysed by silica supported fluoroboric acid as potent antioxidant and anxiolytic agents. Med Chem Res 28, 2200–2217 (2019).
|
| Additional Infomation |
Antioxidant agent-7 (SD-7, Compound 4f) is a benzodiazepine derivative (3,3-dimethyl-11-(4-nitrophenyl)-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one) with potent DPPH radical scavenging activity (IC50 470 nM). It is used in research on oxidative stress-related chronic diseases, including neurodegenerative disorders and inflammatory conditions. It is not approved for clinical therapy. Molecular formula: C21H21N3O3; molecular weight: 363.41.
|
| Molecular Formula |
C21H21N3O3
|
|---|---|
| Molecular Weight |
363.41
|
| Exact Mass |
363.158
|
| CAS # |
82408-04-6
|
| PubChem CID |
302312
|
| Appearance |
Yellow to orange solid powder
|
| Density |
1.31g/cm3
|
| Boiling Point |
565.5ºC at 760 mmHg
|
| Flash Point |
295.8ºC
|
| Index of Refraction |
1.658
|
| LogP |
5.615
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
27
|
| Complexity |
644
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1CC(C)(C)CC2NC3C(NC(C1=2)C1C=CC([N+](=O)[O-])=CC=1)=CC=CC=3
|
| InChi Key |
UGGUUWQHYLAINX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H21N3O3/c1-21(2)11-17-19(18(25)12-21)20(13-7-9-14(10-8-13)24(26)27)23-16-6-4-3-5-15(16)22-17/h3-10,20,22-23H,11-12H2,1-2H3
|
| Chemical Name |
9,9-dimethyl-6-(4-nitrophenyl)-6,8,10,11-tetrahydro-5H-benzo[b][1,4]benzodiazepin-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (343.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7517 mL | 13.7586 mL | 27.5171 mL | |
| 5 mM | 0.5503 mL | 2.7517 mL | 5.5034 mL | |
| 10 mM | 0.2752 mL | 1.3759 mL | 2.7517 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
